Kura Oncology officer plans $54.7K stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. (KURA) reported that its officer Kathleen Ford plans to sell 7,042 shares of common stock, with an aggregate market value of $54,716.34, on approximately November 16, 2026. Ford acquired the shares from the issuer in a PSU transaction on November 13, 2026. The notice lists 92,784,785 common shares outstanding. It also reports two sales in the prior three months: 6,906 performance-based restricted stock units sold September 28, 2026, for gross proceeds of $72,494.35 in a sell-to-cover transaction, and 3,668 sold September 29, 2026, for gross proceeds of $39,436.71 in a 10b5-1 sale.
Key Figures
Key Terms
PSU financial
Performance-Based Restricted Stock Units financial
sell-to-cover financial
10b5-1 Sales regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.